LSL:CA:TSV-LSL Pharma Group Inc. (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.445

Change

0.00 (0.00)%

Market Cap

USD 0.05B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

+0.05 (+0.45%)

USD 0.13B
LOVE:CA Cannara Biotech Inc

+0.01 (+1.67%)

USD 0.07B
ZYUS:CA ZYUS Life Sciences Corporation

N/A

USD 0.06B
SBBC:CA Simply Better Brands Corp

+0.04 (+6.35%)

USD 0.06B
HASH:CA Simply Solventless Concentrate..

-0.01 (-1.75%)

USD 0.05B
DB:CA Decibel Cannabis Company Inc

-0.01 (-7.14%)

USD 0.03B
ROMJ:CA Rubicon Organics Inc

-0.02 (-3.80%)

USD 0.02B
PCLO:CA Pharmacielo Ltd

N/A

USD 0.02B
ELXR:CA Elixxer Ltd

N/A

USD 0.01B
VM:CA Voyageur Pharmaceuticals Ltd

-0.01 (-7.14%)

USD 9.76M

ETFs Containing LSL:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.25% 47% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.25% 47% F 47% F
Trailing 12 Months  
Capital Gain -7.29% 60% D- 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.29% 60% D- 49% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -4.54% N/A N/A 44% F
Dividend Return -4.54% N/A N/A 43% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.71% N/A N/A 98% N/A
Risk Adjusted Return -33.10% N/A N/A 32% F
Market Capitalization 0.05B 75% C 84% B

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector